լƵ

XClose

UCL Department of Biochemical Engineering

Home
Menu

UCL leading £2.5m EPSRC grant to transform CAR-T therapy manufacturing

4 July 2024

UCL will lead a £2.5 million grant from the Engineering and Physical Sciences Research Council (EPSRC) for the innovative project "FAST CAR-T: Faster, Adaptive and Scalable Technologies For CAR-T Manufacture.

Biochemical Engineers at fume hood

UCL will lead a £2.5 million grant from the Engineering and Physical Sciences Research Council (EPSRC) for the innovative project "FAST CAR-T: Faster, Adaptive and Scalable Technologies For CAR-T Manufacture.

The project, co-led by Professor Qasim Rafiq (UCL Biochemical Engineering) and Dr Claire Roddie (UCL Cancer Institute) is funded for three years as part of the EPSRC’s Accelerating the Medicines Revolution Large Grants call.

The project is a UK-wide collaborative effort between UCL, the University of Teesside, and the University of the West of England Bristol. Co-Investigators Dr Stephen Goldrick (UCL Biochemical Engineering), Professor Gary Montague (University of Teesside), and Professor Wendy Phillips (UWE Bristol).

DzԳٱ

Cell and gene therapies (CGTs) are at the forefront of transformative treatments, showcasing remarkable clinical outcomes. CAR-T (Chimeric Antigen Receptor T-cell) therapy, a personalised cancer treatment, has demonstrated the ability to induce lasting remissions in patients with blood cancers previously considered incurable. However, the high cost and complexity of manufacturing CAR-T therapies pose significant challenges. Current treatments can exceed £300,000 due to the intricate, personalised nature of production.

վDz

The FAST CAR-T project aims to revolutionise CAR-T therapy production by making it faster, more adaptable, and scalable. This initiative focuses on three key areas:

  1. Speed: Developing a more rapid manufacturing process for patient-specific CAR-T therapies.
  2. Adaptability: Creating a manufacturing process that can accommodate patient variability.
  3. Scalability: Establishing processes to support the next generation of universal donor CAR-T therapies.

The project will also address the regulatory, operational, and business models needed for decentralised, point-of-care manufacturing.

Team

The FAST CAR-T project involves a multidisciplinary team of 8 investigators and 5 post-doctoral researchers across four institutions: UCL, Royal Free Hospital, University of Teesside, and UWE Bristol. Each partner is a leader in their respective field, bringing expertise in CAR-T bioprocessing, digitalisation, and decentralised manufacturing.

Professor Qasim Rafiq, UCL Biochemical Engineering and Principal Investigator, commented, "This grant represents a significant step forward in our mission to make CAR-T therapies more accessible and affordable. By leveraging the strengths of our academic and clinical partners, we aim to deliver a transformative impact on CAR-T therapy manufacturing."

Dr Claire Roddie, UCL Cancer Institute and Co-Investigator, highlighted the clinical importance of this project, stating, “The FAST CAR-T initiative is a pivotal step towards overcoming the current barriers in CAR-T therapy manufacturing. This project will enable us to bring these life-saving treatments to patients more quickly and efficiently, significantly improving patient outcomes in the fight against cancer”

Professor Gary Montague, University of Teesside and Co-Investigator, added, "Our work on digital tools and process modelling will be crucial for the future of advanced medicines and CAR-T production, ensuring it is resilient and adaptable to patient needs."

Professor Wendy Phillips, UWE Bristol and Co-Investigator, emphasised, "The development of new operational and business models is essential for the widespread adoption of CAR-T therapies at the point of care, making these life-saving treatments available to more patients."

More Information

For more information about the FAST CAR-T project and updates on its progress, please contact and visit the UCL Biochemical Engineering website.

About UCL Biochemical Engineering

UCL Biochemical Engineering is a leading department in the development of bioprocessing and manufacturing technologies for advanced therapies. Our research focuses on innovative solutions to improve the scalability, affordability, and accessibility of next-generation medical treatments.

԰